Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2005-02-22
2005-02-22
Tsang, Cecilia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C568S306000
Reexamination Certificate
active
06858651
ABSTRACT:
The present invention relates to aminocyclohexanol derivatives useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, gallstones, tumors and/or hyperproliferative disorders, and treatment and/or prophylaxis of impaired glucose tolerance and diabetes.
REFERENCES:
patent: 3592824 (1971-07-01), Schut
patent: 20030186984 (2003-10-01), Ackermann et al.
patent: 0 778 264 (1997-06-01), None
patent: 1515629 (1968-01-01), None
patent: WO 02 20483 (2002-03-01), None
patent: WO 02 36584 (2002-05-01), None
Auwerx et al., Atherosclerosis XII, pp. 21-39 (2000).
Brown et al., Pyrimidine reactions. XXII. Relative reactivities of corresponding chloro-, bromo-, and iodopyrimidines in aminolysis., J. Chem. Soc. C (1971), 10, 1889-1891.
Karpavichyus et al., Baccat; Bull. Acad.Sci. USSR Div.Chem.Sci (Engl.Transl.);EN;29;1980;1689-1694.
Wermuth, et al., Practise of Medicinal Chemistry, XP002190259, Table 13.1, pp. 203-237 (1996).
Ackermann Jean
Aebi Johannes
Blum Denise
Chucholowski Alexander
Dehmlow Henrietta
Hoffmann-La Roche Inc.
Johnston George W.
Robinson Binta
Rocha-Tramaloni Patricia S.
Tsang Cecilia
LandOfFree
2,3-oxidosqualene-lanosterol cyclase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2,3-oxidosqualene-lanosterol cyclase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,3-oxidosqualene-lanosterol cyclase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3468318